Business Context and Reporting Period
This Form 8-K Current Report was filed by Catalyst Biosciences, Inc. on September 22, 2017, reporting events occurring on September 19, 2017. The filing primarily addresses the execution of amended and restated employment agreements with key executive officers and an amendment to the non-employee director compensation policy. Note: The request metadata lists "Gyre Therapeutics, Inc.", but the filing text explicitly identifies the registrant as Catalyst Biosciences, Inc.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or liquidity metrics. The document focuses exclusively on executive compensation terms and governance policy changes.
Material Changes and Executive Compensation
On September 19, 2017, the Company entered into amended employment agreements with its CEO and CFO to harmonize provisions regarding severance, constructive termination, and option exercise periods.
Dr. Nassim Usman, Ph.D. (President and CEO)
- Base Salary: $466,796 annually (subject to 2018 review).
- Performance Bonus: Up to 50% of annual salary.
- Severance (Pre-Change of Control): 12 months of base salary and accelerated vesting of options that would have vested over the next 12 months.
- Severance (Post-Change of Control): 12 months of base salary and full accelerated vesting of all remaining unvested options.
- Constructive Termination: Now includes relocation of duties more than 30 miles from the current location.
- Death/Disability: Vested options exercisable within one year of termination.
Mr. Fletcher Payne (Chief Financial Officer)
- Base Salary: $335,244 annually (subject to 2018 review).
- Performance Bonus: Up to 35% of annual salary.
- Severance (Pre-Change of Control): 6 months of base salary and accelerated vesting of options that would have vested over the next 6 months.
- Severance (Post-Change of Control): 9 months of base salary and full accelerated vesting of all remaining unvested options.
- Constructive Termination: Now includes relocation of duties more than 30 miles from the current location.
- Death/Disability: Vested options exercisable within one year of termination.
Other Events and Governance
On September 5, 2017, the Board of Directors amended the non-employee director compensation policy. Directors may now elect to receive their annual compensation in cash or fully vested common stock issued under the 2015 Stock Incentive Plan. Stock issuances are calculated based on the closing price of the Company's common stock on the last business day of the applicable quarter.
Investor Verification Checklist
- Verify the total number of outstanding stock options held by Dr. Usman and Mr. Payne to assess the potential dilution impact of accelerated vesting clauses.
- Review the Company's current cash position to evaluate the ability to fund potential severance payments (up to 12 months for CEO, 9 months for CFO) in a change of control scenario.
- Confirm the specific definitions of "Cause" and "Constructive Termination" in the full text of Exhibits 10.1 and 10.2.
- Monitor future filings for the actual election of stock vs. cash compensation by non-employee directors and the resulting share issuance.